HALT-IT - tranexamic acid for the treatment of gastrointestinal bleeding: Study protocol for a randomised controlled trial

Trials

Volumn 15, Issue 1, 2014, Pages

  Roberts, Ian ^a   Coats, Timothy ^b   Edwards, Phil ^a   Gilmore, Ian ^c   Jairath, Vipul ^d   Ker, Katharine ^a   Manno, Daniela ^a   Shakur, Haleema ^a   Stanworth, Simon ^d   Veitch, Andrew ^e  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e NEW CROSS HOSPITAL   (United Kingdom)

Author keywords

Clinical trials; Gastrointestinal bleeding; Tranexamic acid

Indexed keywords

PLACEBO; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ADULT; ARTICLE; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEALTH STATUS; HUMAN; INTENTION TO TREAT ANALYSIS; LOADING DRUG DOSE; LOWER GASTROINTESTINAL BLEEDING; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEASUREMENT PRECISION; MORBIDITY; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SYSTEMATIC REVIEW (TOPIC); UPPER GASTROINTESTINAL BLEEDING; CLINICAL PROTOCOL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; TIME FACTOR; TREATMENT OUTCOME;

ANTIFIBRINOLYTIC AGENTS; BLOOD TRANSFUSION; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INFUSIONS, INTRAVENOUS; INTENTION TO TREAT ANALYSIS; RECURRENCE; RESEARCH DESIGN; TIME FACTORS; TRANEXAMIC ACID; TREATMENT OUTCOME;

EID: 84934286919     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-450     Document Type: Article

References (42)

1. Button L, Roberts S, Evans P, Goldacre M, Akbari A, Dsilva R, MacEy S, Williams J: Hospitalized incidence and case fatality for upper gastrointestinal bleeding from 1999 to 2007. A record linkage study. Aliment Pharmacol Ther 2011, 33:64-76. 10.1111/j.1365-2036.2010.04495.x.
2. Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR: Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011, 60:1327-1335. 10.1136/gut.2010.228437.
3. Williams JG, Roberts SE, Ali MF, Cheung WY, Cohen DR, Demery G, Edwards A, Greer M, Hellier MD, Hutchings HA, Ip B, Longo MF, Russell IT, Snooks HA, Williams JC: Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence. Gut 2007,56(Suppl 1):1-113.
4. van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, Engels D: Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 2003, 86:125-139. 10.1016/S0001-706X(03)00029-9.
5. British Society of Gastroenterology: UK Comparative Audit of Upper Gastrointestinal Bleeding and the use of Blood. 2007. http://www.bsg.org.uk/pdf_word_docs/blood_audit_report_07.pdf
6. Barkun A, Sabbah S, Enns R, Armstrong D, Gregor J, Fedorak R, Rahme E, Toubouti Y, Martel M, Chiba N, Fallone CA, RUGBE Investigators: The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004, 99:1238-1246. 10.1111/j.1572-0241.2004.30272.x.
7. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Levy V, Poupon R: Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004, 40:652-659. 10.1002/hep.20339.
8. D'Amico G, De Franchis R: Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003, 38:599-612.
9. Lau JY, Sung JJ, Lee KK, Yung MY, Wong SK, Wu JC, Chan FK, Ng EK, You JH, Lee CW, Chan AC, Chung SC: Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000, 343:310-316. 10.1056/NEJM200008033430501.
10. Jairath V, Barkun A: Improving outcomes from acute upper gastrointestinal bleeding. Gut 2012, 61:1246-1249. 10.1136/gutjnl-2011-300019.
11. Rockall TA, Logan RF, Devlin HB, Northfield TC: Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering committee and members of the national audit of acute upper gastrointestinal haemorrhage. BMJ 1995, 311:222-226. 10.1136/bmj.311.6999.222.
12. Barnert J, Messmann H: Diagnosis and management of lower gastrointestinal bleeding. Nat Rev Gastroenterol Hepatol 2009, 6:637-646. 10.1038/nrgastro.2009.167.
13. Farrell JJ, Friedman LS: Review article: the management of lower gastrointestinal bleeding. Aliment Pharmacol Ther 2005, 21:1281-1298. 10.1111/j.1365-2036.2005.02485.x.
14. Longstreth GF: Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1997, 92:419-424.
15. Ker K, Edwards P, Perel P, Shakur H, Roberts I: Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012, 344:e3054. 10.1136/bmj.e3054.
16. The CRASH-2 Collaborators: Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010, 376:23-32.
17. The CRASH-2 Collaborators: The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011, 377:1096-1101.
18. Guerriero C, Cairns J, Perel P, Shakur H, Roberts I: Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. PLoS One 2011, 6:e18987. 10.1371/journal.pone.0018987.
19. WHO: Summary of the Report of the 18th Meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines. Geneva: World Health organization; 2011.
20. Manno D, Ker K, Roberts I: How effective is tranexamic acid for acute gastrointestinal bleeding? BMJ 2014, 348:g1421. 10.1136/bmj.g1421.
21. Gluud LL, Klingenberg SL, Langholz E: Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev 2012., 1: CD006640
22. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P: International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010, 152:101-113. 10.7326/0003-4819-152-2-201001190-00009.
23. Sung JJ, Chan FK, Chen M, Ching JY, Ho KY, Kachintorn U, Kim N, Lau JY, Menon J, Rani AA, Reddy N, Sollano J, Sugano K, Tsoi KK, Wu CY, Yeomans N, Vakil N, Goh KL, Asia-Pacific Working Group: Asia-pacific working group consensus on non-variceal upper gastrointestinal bleeding. Gut 2011, 60:1170-1177. 10.1136/gut.2010.230292.
24. National Institute for Health and Clinical Excellence: Management of Acute Upper Gastrointestinal Bleeding (Clinical Guideline 141). 2012. http://www.nice.org.uk/guidance/cg141/resources/guidance-acute-upper-gastrointestinal-bleeding-management-pdf
25. Ketley D, Woods KL: Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet 1993, 342:891-894. 10.1016/0140-6736(93)91945-I.
26. Prentice CR: Basis of antifibrinolytic therapy. J Clin Pathol Suppl 1980, 14:35-40.
27. Al-Mohana JM, Lowe GD, Murray GD, Burns HG: Association of fibrinolytic tests with outcome of acute upper-gastrointestinal-tract bleeding. Lancet 1993, 341:518-521. 10.1016/0140-6736(93)90278-O.
28. Poller L, Thomson J: Evidence for a relationship between fibrinolysis and haematemesis. Br J Haematol 1973, 24:664.
29. Dunn CJ, Goa KL: Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999, 57:1005-1032. 10.2165/00003495-199957060-00017.
30. Kalavrouziotis D, Voisine P, Mohammadi S, Dionne S, Dagenais F: High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. Ann Thoracic Surg 2012, 93:148-154. 10.1016/j.athoracsur.2011.07.085.
31. Manji RA, Grocott HP, Leake J, Ariano RE, Manji JS, Menkis AH, Jacobsohn E: Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. Can J Anesthesia 2012, 59:6-13. 10.1007/s12630-011-9618-z.
32. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M: High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesthesia Analgesia 2010, 110:350-353. 10.1213/ANE.0b013e3181c92b23.
33. Keyl C, Uhl R, Beyersdorf F, Stampf S, Lehane C, Wiesenack C, Trenk D: High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. Eur J Cardio Thorac 2011, 39:e114-e121. 10.1016/j.ejcts.2010.12.030.
34. Peto R, Baigent C: Trials: the next 50years. Large scale randomised evidence of moderate benefits. BMJ 1998, 317:1170-1171. 10.1136/bmj.317.7167.1170.
35. Straube S, Tramer MR, Moore RA, Derry S, McQuay HJ: Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol 2009, 9:41. 10.1186/1471-230X-9-41.
36. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, Ker K: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2011., 3: CD001886
37. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL: The dose-response relationship of tranexamic acid. Anesthesiology 1995, 82:383-392. 10.1097/00000542-199502000-00009.
38. Wallace M, Shelkey M: Monitoring functional status in hospitalized older adults. Am J Nurs 2008, 108:64-71. quiz 71-62
39. DAMOCLES study group: A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet 2005, 365:711-722.
40. Haybittle JL: Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971, 44:793-797. 10.1259/0007-1285-44-526-793.
41. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977, 35:1-39. 10.1038/bjc.1977.1.
42. Moher D, Schulz KF, Altman DG: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001, 357:1191-1194. 10.1016/S0140-6736(00)04337-3.